| melanoma
Imlygic vs Kimmtrak
Side-by-side clinical, coverage, and cost comparison for melanoma.Deep comparison between: Imlygic vs Kimmtrak with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsKimmtrak has a higher rate of injection site reactions vs Imlygic based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Kimmtrak but not Imlygic, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Imlygic
Kimmtrak
At A Glance
Intralesional injection
Every 2-3 weeks
Oncolytic viral therapy
IV infusion
Weekly
gp100/CD3 T cell engager
Indications
- Melanoma
- melanoma
Dosing
Melanoma Initial dose up to 4 mL at 1 million PFU/mL intralesionally; second dose 3 weeks later up to 4 mL at 100 million PFU/mL; all subsequent doses every 2 weeks up to 4 mL at 100 million PFU/mL.
Melanoma 20 mcg IV on Day 1, 30 mcg IV on Day 8, 68 mcg IV on Day 15, then 68 mcg IV once weekly thereafter; administer by intravenous infusion over 15-20 minutes.
Contraindications
- Immunocompromised patients, including those with primary or acquired immunodeficiency, leukemia, lymphoma, AIDS or other clinical manifestations of HIV infection, or on immunosuppressive therapy
- Pregnant patients
—
Adverse Reactions
Most common (>=25%) Fatigue, chills, pyrexia, nausea, influenza-like illness, injection site pain
Serious Cellulitis (most common grade 3+ reaction), herpetic infection, injection site complications
Postmarketing Disseminated herpetic infections, including serious and fatal cases in immunocompromised patients
Most common (>=30%) Cytokine release syndrome, rash, pyrexia, pruritus, fatigue, nausea, chills, abdominal pain, edema, hypotension, dry skin, headache, vomiting
Serious Cytokine release syndrome, skin reactions, elevated liver enzymes, rashes, pyrexia, hypotension
Pharmacology
Oncolytic viral therapy; genetically modified live attenuated HSV-1 that replicates within tumors causing lysis and release of tumor-derived antigens, and produces GM-CSF to promote an antitumor immune response; exact mechanism of action is unknown.
Tebentafusp-tebn is a bispecific gp100 peptide-HLA-A*02:01 directed TCR CD3 T cell engager; it binds to gp100 peptide on HLA-A*02:01-positive uveal melanoma cells and activates polyclonal T cells to release inflammatory cytokines and cytolytic proteins, resulting in direct lysis of uveal melanoma tumor cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Imlygic
- Covered on 5 commercial plans
- PA (2/12) · Step Therapy (0/12) · Qty limit (0/12)
Kimmtrak
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Imlygic
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Kimmtrak
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Imlygic
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Kimmtrak
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAmgen Safety Net Foundation
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Melanoma: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ImlygicView full Imlygic profile
KimmtrakView full Kimmtrak profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.